Your browser doesn't support javascript.
loading
E3 ubiquitin ligase MID1 ubiquitinates and degrades type-I interferon receptor 2.
Chen, Xiangjie; Zhao, Qian; Xu, Ying; Wu, Qiuyu; Zhang, Renxia; Du, Qian; Miao, Ying; Zuo, Yibo; Zhang, Hong-Guang; Huang, Fan; Ren, Tengfei; He, Jiuyi; Qiao, Caixia; Li, Yue; Li, Shifeng; Xu, Yang; Wu, Depei; Yu, Zhengyuan; Lv, Haitao; Wang, Jun; Zheng, Hui; Yuan, Yukang.
Afiliación
  • Chen X; Institutes of Biology and Medical Sciences, Jiangsu Key Laboratory of Infection and Immunity, Soochow University, Suzhou, China.
  • Zhao Q; Institutes of Biology and Medical Sciences, Jiangsu Key Laboratory of Infection and Immunity, Soochow University, Suzhou, China.
  • Xu Y; School of Biology and Basic Medical Sciences, Soochow University, Suzhou, China.
  • Wu Q; Department of Intensive Care Medicine, the First Affiliated Hospital of Soochow University, Soochow University, Suzhou, China.
  • Zhang R; Department of Intensive Care Unit, Qinghai Provincial People's Hospital, Xining, China.
  • Du Q; Institutes of Biology and Medical Sciences, Jiangsu Key Laboratory of Infection and Immunity, Soochow University, Suzhou, China.
  • Miao Y; Institutes of Biology and Medical Sciences, Jiangsu Key Laboratory of Infection and Immunity, Soochow University, Suzhou, China.
  • Zuo Y; School of Biology and Basic Medical Sciences, Soochow University, Suzhou, China.
  • Zhang HG; Institutes of Biology and Medical Sciences, Jiangsu Key Laboratory of Infection and Immunity, Soochow University, Suzhou, China.
  • Huang F; Institutes of Biology and Medical Sciences, Jiangsu Key Laboratory of Infection and Immunity, Soochow University, Suzhou, China.
  • Ren T; Institutes of Biology and Medical Sciences, Jiangsu Key Laboratory of Infection and Immunity, Soochow University, Suzhou, China.
  • He J; Institutes of Biology and Medical Sciences, Jiangsu Key Laboratory of Infection and Immunity, Soochow University, Suzhou, China.
  • Qiao C; Institutes of Biology and Medical Sciences, Jiangsu Key Laboratory of Infection and Immunity, Soochow University, Suzhou, China.
  • Li Y; Institutes of Biology and Medical Sciences, Jiangsu Key Laboratory of Infection and Immunity, Soochow University, Suzhou, China.
  • Li S; Institutes of Biology and Medical Sciences, Jiangsu Key Laboratory of Infection and Immunity, Soochow University, Suzhou, China.
  • Xu Y; Institutes of Biology and Medical Sciences, Jiangsu Key Laboratory of Infection and Immunity, Soochow University, Suzhou, China.
  • Wu D; School of Biology and Basic Medical Sciences, Soochow University, Suzhou, China.
  • Yu Z; Department of Intensive Care Medicine, the First Affiliated Hospital of Soochow University, Soochow University, Suzhou, China.
  • Lv H; National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, the First Affiliated Hospital of Soochow University, Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China.
  • Wang J; National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, the First Affiliated Hospital of Soochow University, Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China.
  • Zheng H; Department of Oncology, The First Affiliated Hospital of Soochow University, Suzhou, China.
  • Yuan Y; Department of Cardiology, Children's Hospital of Soochow University, Suzhou, China.
Immunology ; 167(3): 398-412, 2022 11.
Article en En | MEDLINE | ID: mdl-35794827
ABSTRACT
Type I interferon (IFN-I) is a common biological molecule used for the treatment of viral diseases. However, the clinical antiviral efficacy of IFN-I needs to be greatly improved. In this study, IFN-I receptor 2 (IFNAR2) was revealed to undergo degradation at the protein level in cells treated with IFN-I for long periods of time. Further studies found a physical interaction between the E3 ubiquitin ligase midline-1 (MID1) and IFNAR2. As a consequence, MID1 induced both K48- and K63-linked polyubiquitination of IFNAR2, which promoted IFNAR2 protein degradation in a lysosome-dependent manner. Conversely, knockdown of MID1 largely restricted IFN-I-induced degradation of IFNAR2. Importantly, MID1 regulated the strength of IFN-I signalling and IFN-I-induced antiviral activity. These findings reveal a regulatory mechanism of IFNAR2 ubiquitination and protein stability in IFN-I signalling, which could provide a potential target for improving the antiviral efficacy of IFN-I.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Interferón Tipo I / Ubiquitina-Proteína Ligasas Idioma: En Revista: Immunology Año: 2022 Tipo del documento: Article País de afiliación: China

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Interferón Tipo I / Ubiquitina-Proteína Ligasas Idioma: En Revista: Immunology Año: 2022 Tipo del documento: Article País de afiliación: China